nidufexor   Click here for help

GtoPdb Ligand ID: 10655

Synonyms: compound 1 [PMID: 31940200] | LMB-763 | LMB763
Compound class: Synthetic organic
Comment: Nidufexor (LMB763) is an orally bioavailable non-bile acid agonist of the ligand-activated nuclear farnesoid X receptor (FXR) that is being developed by Novartis for the treatment of nonalcoholic steatohepatitis (NASH) [1]. FXR agonists reduce steatosis, hepatocellular inflammation, hepatic injury and fibrosis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 84.66
Molecular weight 487.13
XLogP 5.35
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Clc1ccc2c(c1)c1n(C)nc(c1CO2)C(=O)N(Cc1ccc(cc1)C(=O)O)Cc1ccccc1
Isomeric SMILES Clc1ccc2c(c1)c1n(C)nc(c1CO2)C(=O)N(Cc1ccc(cc1)C(=O)O)Cc1ccccc1
InChI InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
Bioactivity Comments
Nidufexor (LMB763) exhibits partial FXR agonistic activity in vitro and effects FXR-dependent gene modulation in vivo [1]. LMB763 reduces steatosis, inflammation, and fibrosis in NASH murine models.
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Farnesoid X receptor Hs Agonist Partial agonist 9.3 pEC50 - 1
pEC50 9.3 (EC50 5x10-10 M) [1]
Description: Determined in a HTRF FXR coactivator interaction assay using GST-tagged hFXR ligand binding domain and biotinylated SRC-1 peptide.